190013-27-5

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-oxo-, 1-methylethyl ester
• Synonyms: 1-Piperidinecarboxylic acid, 4-oxo-, 1-methylethyl ester;Isopropyl 4-oxopiperidine-1-carboxylate;4-Oxopiperidine-1-carboxylic acid isopropyl ester
• CAS NO: 190013-27-5
• Molecular Formula: C₉H₁₅NO₃
• Molecular Weight: 185.22
• Mol File: 190013-27-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-oxo-, 1-methylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-oxo-, 1-methylethyl ester(190013-27-5)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-oxo-, 1-methylethyl ester(190013-27-5)

Safety Data

• Hazardous Substances Data: 190013-27-5(Hazardous Substances Data)

Usage

Use as intermediate

Mevalonolactone is commonly used as an intermediate in the synthesis of various pharmaceuticals and natural products. This means that it is a key component in the production of other compounds, acting as a starting material or building block in chemical reactions.

Physical properties

White crystalline solid This describes the appearance of Mevalonolactone, which is a white, crystalline solid.

Solubility

Soluble in water and organic solvents This indicates that Mevalonolactone can dissolve in both water and various organic solvents, which can be important for its use in chemical reactions and applications.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 108-23-6 isopropyl chloroformate 
• 41979-39-9 4-piperidone hydrochloride 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 1209007-75-9 1,4-dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid isopropyl ester 

Downstream Products

• 1380349-82-5 isopropyl 4-(6-(benzyloxy)-5-(hydroxymethyl)pyrimidin-4-yl)-4-hydroxypiperidine-1-carboxylate 
• 1380349-83-6 isopropyl 4-(benzyloxy)-5H-spiro[furo[3,4-d]pyrimidine-7,4'-piperidine]-1'-carboxylate 
• 1416137-41-1 C₂₁H₂₇FN₄O₄S 

Relevant articles and documents

N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF

The present invention relates to compounds of general formula I, wherein R1, LP, HetAr1, (Het)Ar2 and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

N-CYCLOPROPYL-N-PIPERIDINYL-AMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES THEREOF

The present invention relates to compounds of general formula (I), wherein R1, LP, HetAr1, (Het)Ar2 and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

NOVEL PYRROLOY2,3-d¨PYRIMIDINE COMPOUND

Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group repre

GPR119 Receptor Agonists

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

[6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS

Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n2, n3, n4, A, B, D, E, G, J, Y, R1 and R2 are defined herein.